31 results about "Intellectual disability" patented technology

The invention discloses a health care product capable of improving sleep. The health care product has the beneficial effects that the formula of the health care product contains kudzuvine root which is compatible with longan, spina date seed, milkwort root and Chinese arborvitae kernel; the health care product follows the principle of treatment based on syndrome differentiation in the traditional Chinese medicine science; the medicines in the formula supplement each other; the health care product has the obvious function of improving sleep, simultaneously can alleviate the diseases of patients with hypertension, hyperlipidemia, hyperglycemia, migraine and other cardiovascular and cerebrovascular diseases, and can conduce to treating senile dementia, dysgnosia, poor memory, poor metabolism and other diseases of some middle-aged and old people.

A therapeutic method for treating apraxia of speech in children. The child can also be diagnosed with autism, mental retardation, dyslexia. Verbal development stages and nonverbal development stages are tested and observed. If a child demonstrates at least 18 to 24 month development stage of either the verbal development or the non-verbal development, a therapeutic dosage of dopamine agonistic medicine is administered to the child in addition to speech therapy and language training.

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formulawherein each symbol is as defined in the present specification, or a salt thereof.

The invention provides a back frame for reducing the degree of a fall injury. The back frame aims at achieving the purpose of reducing the injury degree when the elderly fall down backwards. The backframe comprises a support rod, a universal joint, a back support and a buzzer. The support rod is internally provided with a spring, the upper end of the support rod is connected with the universal joint, the lower end of the support rod is provided with the buzzer, the other end of the universal joint is connected with the back support, and the universal joint is internally provided with a fixedgear. The back frame has the advantages that when the elderly fall down backwards accidentally, the support rod can be kept in a vertical state, the bottom of the support rod can be in contact with the ground at first, the falling strength is buffered by the spring in the support rod, transmitted to the back support and decomposed, the gravity centers of the elderly are low at this moment, large damage cannot be caused when the elderly continue to fall down, the buzzer beeps at the same time, and pedestrians are prompted to help the elderly. Besides the elderly, the back frame is also suitablefor other people with action and intelligence disorders.

The invention relates to application of a dcf1 gene to regulation and control over expression of ATP1B1. Two types of mouse detection including a wild type (as reference) and dcf1 knockout are adopted, and it is found that the dcf1 gene has influences on astrocytes through ATP1B1; it is found through cell immunofluorescence observation that after dcf1 knockout is conducted, the sizes of the astrocytes are reduced; then cellular immunofluorescence and co-immunoprecipitation prove the interaction between DCF1 and the ATP1B1 with the function of influencing the sizes of the astrocytes, research on the interaction relationship and the upstream and downstream adjustment relationship between the DCF1 and the ATP1B1is conducted, meanwhile, an RNA interference technology is utilized to lower the expression quantity of the ATP1B1, it is observed that abnormity of the astrocytes is relieved, and the treatment potential of the DCF1 for dysgnosia caused by abnormity of the astrocytes is finally proved.

A therapeutic method for treating apraxia of speech in children. The child can also be diagnosed with autism, mental retardation, dyslexia. Verbal development stages and nonverbal development stages are tested and observed. If a child demonstrates at least 18 to 24 month development stage of either the verbal development or the non-verbal development, a therapeutic dosage of dopamine agonistic medicine is administered to the child in addition to speech therapy and language training.

The invention discloses an agent capable of improving intelligence level of patients suffering from intellectual disability. The agent is prepared from the following raw material medicines in parts by weight: 10-20 parts of gorgon fruits, 15-30 parts of lotus leaf, 15-20 parts of gray polypody, 15-30 parts of cassia twig, 9-15 parts of stone-like omphalia, 8-16 parts of flickingeria comata, 20-30 parts of semen sesami nigrum, 15-20 parts of angelica sinensis, 15-30 parts of poria with hostwood, 3-6 parts of ruddle, 5-9 parts of digua fig stem and leaf, 8-12 parts of longstalk condorvine herb, 8-12 parts of fructus viticis, 15-30 parts of wolfberry and 15-30 parts of fructus alpiniae oxyphyllae. The agent disclosed by the invention has the excellent effects that the traditional medicine properties and the modern pharmacology of traditional Chinese medicine are organically combined, the drugs are used to form a prescription, and the curative effect is improved; the traditional Chinese medicine has the effects of nourishing liver and kidney, benefiting qi for activating blood circulation and invigorating the brain and improving the intelligence, is capable of obviously improving the intelligence level of the patients suffering from intellectual disability, is safe and does not have any side effect; and moreover, the drug source is readily available, the cost of the medicinal materials is low, and the burdens of patients can be alleviated.

The invention discloses nucleic acid related to X-linked intellectual disability, a gene mutant and an application thereof. Compared with a wild type OPHN1 gene, the nucleic acid related to the X-linked intellectual disability has c.1534G>T mutation. The nucleic acid disclosed by the invention is a new mutated nucleic acid on the OPHN1 gene related to the X-linked intellectual disability, and whether a biological sample suffers from the X-linked intellectual disability or not can be effectively detected by detecting whether the nucleic acid exists in the biological sample or not. The discoveryof the pathogenic mutation site on the OPHN1 gene further expands and perfects the detection and research of the X-linked intellectual disability, and provides a new detection site, a new detection method and a new detection way for the diagnosis or treatment of the disease.

The invention discloses a cerebrovascular therapeutic instrument, which comprises a host and an electrode, the electrode comprises an electrode piece and a ball-type electroencephalogram electrode, and the electrode piece and the ball-type electroencephalogram electrode are connected to the host, the ball-type electroencephalogram electrode comprises a liquid storage bottle and a conductive head,wherein the liquid storage bottle is provided with a conductive liquid and a conductive wire, the conductive wire is connected to the conductive head and the host, and the conductive head is rolled and detachably arranged at a bottleneck of the liquid storage bottle. The electrostimulation current emitted by the cerebrovascular therapeutic instrument disclosed by the invention is the one-way pulsecurrent, which can pass through a brain skull with a relatively low conductivity as well as directly and effectively stimulates the cranial nerve and the cerebral blood vessel, and the cerebrovascular therapeutic instrument provides a new prevention and treatment means for cerebrovascular diseases such as cerebral infarction, dementia, cerebral hemorrhage, headache, encephalitis, dizziness, sequelae of brain trauma, muscle disorders and mental retardation.

The invention discloses a pharmaceutical composition containing 4-hydroxide radical-2-oxo-1-pyrrolidine acetamide and the vitamin E and application of the pharmaceutical composition. The pharmaceutical composition containing 4-hydroxide radical-2-oxo-1-pyrrolidine acetamide and the vitamin E has a synergistic effect in the treatment process of neuromotor dysfunction and impaired memory dysfunction caused by vascular dementia and senile dementia, wherein the vitamin E can remarkably improve the treatment effect of oxiracetam. Accordingly, the effective dose of oxiracetam is reduced, the dosage is reduced, and adverse reaction is reduced after the pharmaceutical composition is applied for a long time. In this way, the pharmaceutical composition can more effectively treat intellectual disability of a dementia patient, the treatment effect can be achieved through the small dosage, and therefore the pharmaceutical composition is suitable for clinical use.

The invention relates to a fall sensor circuit, in particular to a fall sensor circuit applied to a mobile phone. Its characteristic is that the analog data collected by the sensor is transmitted to the single-chip microcomputer, and the digital signal obtained by the single-chip microcomputer is monitored by the internal analog-to-digital conversion circuit. The transmitting circuit automatically sends predetermined distress information, and its device is composed of a data acquisition module, a control module and a voltage conversion module. The fall sensor circuit proposed by the present invention has simple hardware structure, fewer chips and low power consumption. The present invention is particularly suitable for the elderly, children, mentally handicapped people and patients who are prone to falls.

The invention discloses a foot-suspended doll template for psychological rehabilitation training, and belongs to the technical field of medical rehabilitation equipment and appliances. According to the structure of the foot-suspended doll template for psychological rehabilitation training, a main template is a rectangular plate, the four corners of the main template are provided with fixing holes correspondingly, the upper middle end of the main template is provided with a head template, an eye line slot is transversely arranged at the upper end of the head template, the lower end of the eye line slot is symmetrically provided with eye template columns, the lower ends of the two sides of the head template are provided with first hair template columns correspondingly, the side lower ends of the first hair template columns are provided with second hair template columns correspondingly, the lower end of the head template is symmetrically provided with neck template columns, the side lower ends of the neck template columns are symmetrically provided with arm template columns correspondingly, and the lower ends of the arm template columns are symmetrically provided with leg template columns. The template is used for winding a foot-suspended doll, mental patients or patients with intellectual disabilities can become interested in hand making, the manipulative ability of the patients is trained in the winding process, and training stimulation is beneficial to patient rehabilitation.

The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and / or a disorder belonging to the Autism Spectrum Disorder (ASD) and / or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and / or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and / or a disorder belonging to the Autism Spectrum Disorder (ASD) and / or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.

The invention relates to a pathogenic gene model of mental retardation and a building method and application of the pathogenic gene model. The pathogenic gene model has the advantages that the pathogenic gene related to a corresponding patient with the mental retardation is found by analyzing the peripheral blood whole genome DNA of the patient with the mental retardation, the family members of the patient and normal people without the mental retardation, the pathogenesis of the mental retardation can be learned about favorably, and prenatal diagnosis and prevention can be achieved.

The present invention provides methods and compositions for diagnosing and treating intellectual disability (ID). The invention also provides methods and compositions for developing and using in-vitro and in vivo models for diagnosis and treatment as well as testing.

The application provides a device for improving the concentration of mentally handicapped children, including: a support frame, a fountain module, a steel ball, a mobile frame assembly and a pressing block assembly arranged on the support frame, and two rows of partitions on the top frame of the support frame. An S-shaped channel is formed between the blocks; the moving frame assembly is located below the top frame, and the moving frame assembly includes a moving frame that slides longitudinally, an annular sleeve that slides horizontally, and an elastic clamping claw arranged on the annular sleeve; the operation of the pressing block assembly can make The elastic clamping claws are opened; the fountain module includes a fountain piece, a chute and a pricking needle arranged between the fountain piece and the chute, and the pricking needle moves up under the action of the pressing spring; the steel ball is located at the jaw of the elastic clamping claw , the top of the steel ball is higher than the bottom of the spacer, and the released steel ball falls into the chute, and then pushes the needle to move to make the balloon of the flower tube burst. This application can adjust the training difficulty, and the training effect is good.

The present invention relates to a novel serine derivative compound having improved blood-brain barrier (BBB) permeability, and a use of same, and more specifically, to a novel serine derivative compound having further improved BBB permeability compared to L-serine, and a pharmaceutical composition comprising the compound as an effective compound for preventing or treating / alleviating central nervous system diseases, such as cognitive disorders, intellectual disabilities, microcephaly, epilepsy, neurodevelopmental disorders, dementia, autism spectrum disorders, Down syndrome, Rett syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. A compound of chemical formula (I) or a pharmaceutically acceptable salt thereof asan effective component for the pharmaceutical composition of the present invention for preventing or treating central nervous system diseases exhibits significantly improved BBB permeability comparedto L-serine, and activates the propagation of neurons, and through the neuroprotective effect that inhibits oxidative stress-induced mitochondrial membrane potential disruption and / or endoplasmic reticulum stress-induced apoptotic neuronal cell death, exhibits desirable effects in the prevention, treatment, and alleviation of central nervous system diseases, such as cognitive disorders, intellectual disabilities, microcephaly, epilepsy, neurodevelopmental disorders, dementia, autism spectrum disorders, Down syndrome, Rett syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease,Huntington's disease, and amyotrophic lateral sclerosis. Thus, the compound is an extremely useful invention in the drug industry, food industry, and livestock industry.

The invention discloses a nucleic acid related to X-linked mental retardation, a gene mutant and application thereof. The nucleic acid associated with X‑linked intellectual disability has a c.1534G>T mutation compared with the wild-type OPHN1 gene. The nucleic acid of the present invention is a new mutated nucleic acid on the OPHN1 gene related to X-linked mental retardation. By detecting whether the nucleic acid exists in the biological sample, it can effectively detect whether the biological sample suffers from X-linked mental retardation. The discovery of the pathogenic mutation site on the OPHN1 gene has further expanded and improved the detection and research of X-linked intellectual disability, and provided a new detection site, as well as a new detection method and approach for the diagnosis or treatment of the disease.

The invention relates to application of a dcf1 gene to regulation and control over expression of ATP1B1. Two types of mouse detection including a wild type (as reference) and dcf1 knockout are adopted, and it is found that the dcf1 gene has influences on astrocytes through ATP1B1; it is found through cell immunofluorescence observation that after dcf1 knockout is conducted, the sizes of the astrocytes are reduced; then cellular immunofluorescence and co-immunoprecipitation prove the interaction between DCF1 and the ATP1B1 with the function of influencing the sizes of the astrocytes, research on the interaction relationship and the upstream and downstream adjustment relationship between the DCF1 and the ATP1B1is conducted, meanwhile, an RNA interference technology is utilized to lower the expression quantity of the ATP1B1, it is observed that abnormity of the astrocytes is relieved, and the treatment potential of the DCF1 for dysgnosia caused by abnormity of the astrocytes is finally proved.

The present invention provides methods and compositions for diagnosing and treating intellectual disability (ID). The invention also provides methods and compositions for developing and using in-vitro and in vivo models for diagnosis and treatment as well as testing.

The invention discloses a preparation method of a health product for improving sleep. An excipient, Maca, ginseng, fructus rosae laevigatae, actinolite, eucommia ulmoide, acanthopanax root, gastrodia elata, rehmannia, bighead atractylodes rhizome, lily, deer-horn gelatin, yerbadetajo herb, achyranthes bidentata and a lubricating agent are weighted; the preparation method is simple, low in cost and reasonable in compatibility, the principle of traditional Chinese medicine treatment according to syndrome differentiation is abided, various medicines of the formula supplement each other, the effect of improving sleep is remarkable, the health product for improving sleep is non-toxic and harmless for a human body and has the health effect of improving the immunity, and the product has high safety; functions of resisting fatigue, resisting anoxia, calming and promoting phagocytosis of mononuclear macrophage are achieved, sleep, endurance and non-specific resistance can be improved, the immunity of the body is enhanced, and the disease resistance is improved; the sleep effect improving condition is good after a certain treatment course of insomniac; after being taken by middle aged and elderly people for a certain time, the health product can improve uneasy sleep and is favorable for treating diseases such as senile dementia, dysgnosia, poor memory and bad metabolism.

Angelman syndrome is a genetic neurological disorder with characteristics including delayed development, intellectual disability, severe speech impairment, and problems with movement and balance. Provided herein are polynucleotides, vectors, polypeptides, cells, compositions, kits and methods to treat Angelman syndrome.

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formulawherein each symbol is as defined in the present specification, or a salt thereof.

The invention discloses an educational toy for disabled children, comprising a base, the base is connected with a robot body through an automatic rotation mechanism, a display screen, a robot arm and a robot head are respectively arranged on the robot body, and the robot head is A switch, camera equipment, recording equipment, broadcasting equipment, control system and power supply device are provided, and the control system is respectively connected with the switch, camera equipment, recording equipment, broadcasting device and automatic rotation mechanism signal, and the power supply device is respectively connected to the The control system, switch, camera equipment, recording equipment, broadcasting equipment and automatic rotating mechanism are electrically connected. The invention allows the robot to have a dialogue with the mentally disabled children, so that the mentally disabled children can practice sentences by speaking more, and at the same time correct the problem of inaccurate pronunciation of the mentally disabled children, so that the language of the mentally disabled children can be well developed.

The invention discloses a shape awareness character forming method for children with mental disturbance, which comprises the following steps of: according to a character forming principle that Chinese characters form a form expression, taking a four-book character forming method as a basis, taking a character learning card as a carrier, adopting a vivid picture as a form, understanding the expression from the form and forming a character forming graph, and teaching a teacher in a form of telling a story. Vivid and deductive teaching is carried out, then children with intellectual disturbance are guided to construct fonts of Chinese characters, and the children with intellectual disturbance are guided to actively understand the Chinese characters in the process of exploring character sources, fonts, meanings and pronunciation of the Chinese characters; and understanding of the Chinese characters is deepened through writing strokes, stroke orders, word combination and sentence making of the Chinese characters. According to the method, a linked bridge is built between the specific situation created by the vivid picture and modern abstract Chinese characters, multiple senses of children with intellectual disability are aroused by applying multiple strategies such as image and deduction, and the children with intellectual disability are guided to actively understand Chinese characters in the process of exploring Chinese character sources, fonts, meanings, pronunciation and the like; and children with intellectual disturbance are helped to enhance understanding and memorizing of Chinese characters.

The angel syndrome is a hereditary neurological disorder, and is characterized by development retardation, intellectual disability, serious speech disorder and exercise and balance problems. Provided herein are polynucleotides, vectors, polypeptides, cells, compositions, kits and methods for treating angel syndrome.

The invention discloses a health care product for improving sleep. The formula of the invention contains kudzu root, which is compatible with longan, wild jujube kernel, polygala, and baiziren, and follows the principle of syndrome differentiation and treatment in traditional Chinese medicine. The effect of sleep; in addition to the effect of improving sleep, it can also alleviate the symptoms of patients with cardiovascular and cerebrovascular diseases such as hypertension, hyperlipidemia, hyperglycemia and migraine. For some middle-aged and elderly people, it can also help treat the elderly Sexual dementia, mental retardation, poor memory, poor metabolism and other diseases.

The present invention provides a mutation site of an ATRX gene related to intellectual disability, the mutation site is located in intron 24 of the ATRX gene, and the mutation information of the mutation site is: c.5786+4 (IVS24) A>G (NM_000489.6); at the same time, the present invention also provides a DNA detection kit and an mRNA detection kit for auxiliary diagnosis of intellectual disability, respectively, the DNA detection kit is used for the above-mentioned The mutation site is detected, and the mRNA detection kit is used to detect the mRNA transcribed from the mutated ATRX gene. The mutation site described in the first aspect and the result obtained from the transcription of the ATRX gene can be directly detected by first-generation sequencing. The mRNA of this mutation clarifies the pathogenicity of this mutation, reveals the pathogenesis of intellectual disability caused by this mutation, and can also be used for accurate diagnosis of ATRX gene-related intellectual disability diseases.